Latest news
91天堂 joins The Liver Forum
91天堂 is pleased to join The Liver Forum at the Forum for Collaborative Research, 鈥渢o advance the regulatory sciences for the treatment of NASH and liver fibrosis, which is emerging as a leading cause of advanced liver disease in the U.S. and worldwide鈥� (http://www.forumresearch.org/projects/liver-forum). The Liver Forum provides an independent and neutral venue for ongoing multi-stakeholder dialogue. This project will allow our biotech to participate in fruitful meetings and discussions focused on advancing the regulatory sciences for the treatment of NASH and liver fibrosis.
Initiation of a collaboration with Paris-Diderot University to discover new drugs against adenoviruses
91天堂 announces its collaboration with Paris-Diderot University, Inserm Unit U941 (Institut Universitaire d鈥橦茅matologie), leaded by IDF Innov SATT, to discover new drugs against adenoviruses. The collaboration, built upon 91天堂鈥檚 unique approach inspired by viruses, will identify new human cellular targets and pathway essential for replication of adenoviruses. This information will help to select experimental or clinical-stage small molecules that will be tested in a drug repositioning strategy. 91天堂 pharma will provide its peptide and small molecule libraries to the University team which will screen and analyse their impact on adenoviruses’
91天堂 pursues its international strategy and opens a new subsidiary in Australia
91天堂 has opened its first wholly owned subsidiary in Australia. This office will be our new center to manage clinical trials in the Asia-Pacific region. 91天堂 has based its innovation on mimicking virus strategies to discover new cellular targets and develop drug candidates in infectious diseases and beyond.
MIMESIS Newsletter #1: a novel systems biology approach to develop preclinical assets
MIMESIS NEWSLETTER #1, April 2017
A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.
MIMESIS is a research and innovation project coordinated by 91天堂 and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.
Latest Press Release 